
Jean-Sébastien Delisle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7880098/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study. Lancet Haematology,the, 2020, 7, e134-e145.	4.6	138
2	TGF-Î ² in T Cell Biology: Implications for Cancer Immunotherapy. Cancers, 2018, 10, 194.	3.7	132
3	Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. Journal of Clinical Investigation, 2014, 124, 4807-4822.	8.2	74
4	T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nature Medicine, 2005, 11, 1222-1229.	30.7	71
5	BK Polyomavirus and the Transplanted Kidney. Transplantation, 2016, 100, 2276-2287.	1.0	70
6	Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-l-associated epitopes. Immunity, 2021, 54, 737-752.e10.	14.3	58
7	VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation. Journal of Immunology, 2016, 197, 3927-3935.	0.8	43
8	Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-γ receptor-deficient hosts. Blood, 2008, 112, 2111-2119.	1.4	42
9	SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. Blood, 2011, 117, 1734-1744.	1.4	42
10	T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies. Frontiers in Immunology, 2020, 11, 276.	4.8	38
11	Immunoregulatory CD4-CD8- T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer. Frontiers in Immunology, 2013, 4, 6.	4.8	33
12	Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. Journal of Translational Medicine, 2015, 13, 123.	4.4	24
13	Clinical-Scale Rapid Autologous BK Virus-Specific T Cell Line Generation From Kidney Transplant Recipients With Active Viremia for Adoptive Immunotherapy. Transplantation, 2017, 101, 2713-2721.	1.0	19
14	TGFβ Programs Central Memory Differentiation in <i>Ex Vivo</i> –Stimulated Human T Cells. Cancer Immunology Research, 2019, 7, 1426-1439.	3.4	19
15	T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. Cancers, 2021, 13, 598.	3.7	19
16	T Cell Activation Leads to Protein Kinase CÎ, Dependent Inhibition of TGF-β Signaling. Journal of Immunology, 2010, 185, 1568-1576.	0.8	16
17	Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Reviews, 2014, 28, 249-261.	5.7	16
18	Early exposure to interleukin-21 limits rapidly generated anti–Epstein-Barr virus T-cell line differentiation. Cytotherapy, 2015, 17, 496-508.	0.7	16

JEAN-SéBASTIEN DELISLE

#	Article	IF	CITATIONS
19	Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity. Biology of Blood and Marrow Transplantation, 2019, 25, 19-25.	2.0	16
20	p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells. Frontiers in Immunology, 2021, 12, 698565.	4.8	16
21	Roles of Transforming Growth Factor-Ĵ² in Graft-versus-Host and Graft-versus-Tumor Effects. Biology of Blood and Marrow Transplantation, 2012, 18, 1329-1340.	2.0	15
22	Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts. Cancer Gene Therapy, 2000, 7, 757-765.	4.6	14
23	On-chip refractive index cytometry for whole-cell deformability discrimination. Lab on A Chip, 2019, 19, 464-474.	6.0	13
24	Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2020, 26, 157-161.	2.0	13
25	Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers. Current Drug Targets, 2017, 18, 281-295.	2.1	12
26	UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections. Transplantation and Cellular Therapy, 2021, 27, 76.e1-76.e9.	1.2	11
27	The Importance of Single-Mode Behavior in Silicon-On-Insulator Rib Waveguides With Very Large Cross Section for Resonant Sensing Applications. IEEE Journal of Selected Topics in Quantum Electronics, 2016, 22, 241-248.	2.9	10
28	Leukoreduction system chambers are a reliable cellular source for the manufacturing of T ell therapeutics. Transfusion, 2019, 59, 1300-1311.	1.6	9
29	Myeloidâ€resident neuropilinâ€1 promotes choroidal neovascularization while mitigating inflammation. EMBO Molecular Medicine, 2021, 13, e11754.	6.9	9
30	High-throughput refractive index-based microphotonic sensor for enhanced cellular discrimination. Sensors and Actuators B: Chemical, 2018, 266, 255-262.	7.8	8
31	Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leukemia Research, 2019, 79, 75-80.	0.8	8
32	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. Bone Marrow Transplantation, 2022, 57, 252-260.	2.4	6
33	Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma. Blood Cancer Journal, 2022, 12, 3.	6.2	5
34	Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Reviews, 2023, 57, 100991.	5.7	5
35	Newly diagnosed multiple myeloma patients treated with tandem autoâ€allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clinical Transplantation, 2020, 34, e14099.	1.6	4
36	Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective. Transplantation and Cellular Therapy, 2022, 28, 145-151.	1.2	4

JEAN-SéBASTIEN DELISLE

#	Article	IF	CITATIONS
37	Single UM171â€expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. European Journal of Haematology, 2020, 105, 808-811.	2.2	3
38	Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival. Blood, 2018, 132, 4658-4658.	1.4	3
39	UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections. Blood, 2020, 136, 36-37.	1.4	2
40	Pneumatosis Coli Associated to Severe Intestinal Graft Versus Host Disease Following Hematopoietic Cell Transplantation: Risk Factors and Dismal Outcome. Biology of Blood and Marrow Transplantation, 2013, 19, S333.	2.0	1
41	Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia. Blood, 2015, 126, 2562-2562.	1.4	1
42	Prompt Treatment of Respiratory Syncytial Virus with Inhaled Ribavirin and IVIG in High Risk Allogeneic Stem Cell Transplant Recipients Significantly Diminishes Mortality. Biology of Blood and Marrow Transplantation, 2013, 19, S258-S259.	2.0	0
43	TGF-β signaling favors central memory differentiation of ex-vivo stimulated human T cells. Experimental Hematology, 2014, 42, S30.	0.4	Ο
44	Favorable Long-Term Survival of Newly Diagnosed Multiple Myeloma Patients Using a Frontline Outpatient Tandem Approach. Biology of Blood and Marrow Transplantation, 2016, 22, S353-S354.	2.0	0
45	Bortezomib Consolidation after Allogeneic Nonmyeloablative Transplantation to Improve Outcome in Poor Prognosis Multiple Myeloma Patients: A Preliminary Safety Report. Biology of Blood and Marrow Transplantation, 2016, 22, S352-S353.	2.0	0